1.Research progress in perioperative immunotherapy for non-small cell lung cancer
Yuanyuan XU ; Feng MAO ; Xiaoke CHEN ; Qiang TAN ; Qingquan LUO
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2026;33(02):318-325
It is very limited that the benefit of perioperative chemotherapy in early non-small cell lung cancer (NSCLC), and the 5-year survival rate is only 5% higher than surgery. Antibodies that block programmed cell death protein 1/programmed death-ligand 1 significantly improve the survival of advanced NSCLC. The value of immunotherapy in early NSCLC is also being explored. This paper firstly summarized and analyzed the progress of immunotherapy in the perioperative period of NSCLC. Secondly, the safety and feasibility of surgical resection after neoadjuvant immunotherapy were discussed. Finally, the clinical value of different therapeutic efficacy prediction indicators was summarized, in order to clarify the current status of immunotherapy in the perioperative period, so as to improve the clinical benefits of early NSCLC patients.
2.The current status and prospects of artificial intelligence in the diagnosis and treatment of pancreatic cancer
Jinyin ZHANG ; Qingquan TAN ; Nengwen KE ; Xubao LIU
Chinese Journal of General Surgery 2025;34(3):418-427
Artificial intelligence(AI)has demonstrated great potential in the diagnosis and treatment of pancreatic cancer.It plays an important role in medical imaging analysis,pathological slide recognition,drug efficacy and prognosis prediction,as well as new drug development by leveraging deep learning algorithms.Despite challenges such as data acquisition and model interpretability,advancements in technology and data sharing are expected to further enhance its role in early screening,personalized treatment,and innovative drug discovery for pancreatic cancer,ultimately improving patient outcomes.
3.The current status and prospects of artificial intelligence in the diagnosis and treatment of pancreatic cancer
Jinyin ZHANG ; Qingquan TAN ; Nengwen KE ; Xubao LIU
Chinese Journal of General Surgery 2025;34(3):418-427
Artificial intelligence(AI)has demonstrated great potential in the diagnosis and treatment of pancreatic cancer.It plays an important role in medical imaging analysis,pathological slide recognition,drug efficacy and prognosis prediction,as well as new drug development by leveraging deep learning algorithms.Despite challenges such as data acquisition and model interpretability,advancements in technology and data sharing are expected to further enhance its role in early screening,personalized treatment,and innovative drug discovery for pancreatic cancer,ultimately improving patient outcomes.
4.Chinese expert consensus on robot-assisted pulmonary resections
Qingquan LUO ; Shumin WANG ; Hecheng LI ; Jian HU ; Wenjie JIAO ; Qunyou TAN
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2020;27(10):1119-1126
Robotic surgery system has been widely used in various types of pulmonary resections. With the unremitting efforts of Chinese thoracic surgeons, the quantity and quality of robotic pulmonary resections in China have reached a remarkable level. With the development and rapid promotion of this technology, the popularity of robotic surgery is also increasing. In order to standardize the clinical practice, guarantee the quality of treatment and promote the development of robotic pulmonary resections, the Committee of Thoracic Surgery, Doctor Society of Medical Robotics, Chinese Medical Doctor Association organized relevant domestic experts to formulate the consensus of Chinese clinical experts on robot-assisted lung cancer surgery.
5.PCGF6 regulates stem cell pluripotency as a transcription activator via super-enhancer dependent chromatin interactions.
Xiaona HUANG ; Chao WEI ; Fenjie LI ; Lumeng JIA ; Pengguihang ZENG ; Jiahe LI ; Jin TAN ; Tuanfeng SUN ; Shaoshuai JIANG ; Jia WANG ; Xiuxiao TANG ; Qingquan ZHAO ; Bin LIU ; Limin RONG ; Cheng LI ; Junjun DING
Protein & Cell 2019;10(10):709-725
Polycomb group (PcG) ring finger protein 6 (PCGF6), though known as a member of the transcription-repressing complexes, PcG, also has activation function in regulating pluripotency gene expression. However, the mechanism underlying the activation function of PCGF6 is poorly understood. Here, we found that PCGF6 co-localizes to gene activation regions along with pluripotency factors such as OCT4. In addition, PCGF6 was recruited to a subset of the super-enhancer (SE) regions upstream of cell cycle-associated genes by OCT4, and increased their expression. By combining with promoter capture Hi-C data, we found that PCGF6 activates cell cycle genes by regulating SE-promoter interactions via 3D chromatin. Our findings highlight a novel mechanism of PcG protein in regulating pluripotency, and provide a research basis for the therapeutic application of pluripotent stem cells.

Result Analysis
Print
Save
E-mail